Shanghai Ruizhou Biotechnology

Ruizhou Biotech is a biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative targeted protein degradation (TPD) medicines. The company utilizes a proprietary platform to design bifunctional molecules, including PROTACs and molecular glues, that recruit E3 ligases to degrade disease-causing proteins. Their research primarily focuses on addressing "undruggable" targets in oncology and immunology, with a particular emphasis on overcoming drug resistance in solid tumors. Ruizhou Biotech's pipeline features several early-stage programs targeting hormone receptors and other key drivers of cancer progression. The firm is backed by prominent venture capital investors and aims to translate cutting-edge TPD science into clinical therapies.